Centrum für Hämatologie und Onkologie Bethanien

Update Breast Cancer 2021 Part 1-Prevention and Early Stages (2021) Stickeler E, Aktas B, Behrens A, Belleville E, Ditsch N, Fasching P, Fehm TN, et al. Journal article, Review article Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy (2021) Furlanetto J, Möbus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, Lübbe K, et al. Journal article Ribecca - a phase 3b, multi-center, open label study for women with estrogen receptor positive, locally advanced or metastatic breast cancer treated with ribociclib (lee011) in combination with letrozole: Final results (2021) Reinisch M, Nusch A, Decker T, Hartkopf A, Heinrich BJ, Kurbacher CM, Fuchs R, et al. Conference contribution Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer (2021) Schneeweiss A, Michel LL, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, et al. Journal article Efficacy and safety of ribociclib (RIB) in combination with letrozole (LET) in patients with estrogen receptorepositive advanced breast cancer (ABC): Secondary and exploratory results of phase 3b RIBECCA study (2021) Decker T, Fasching P, Nusch A, Hartkopf A, Heinrich BJ, Kurbacher CM, Fuchs R, et al. Conference contribution Prognosis of Patients with Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial (2021) Friedl TWP, Fehm T, Mueller V, Lichtenegger W, Blohmer J, Lorenz R, Forstbauer H, et al. Journal article Use of a molecular Registry (PRAEGNANT) for Patient-Selection and Biomarker-Analysis for the SHERBOC Study (2020) Hübner H, Kurbacher C, Kuesters G, Hartkopf AD, Lux MP, Huober J, Volz B, et al. Conference contribution Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triplenegative breast cancer, TNBC) (PM(Cb)) for patients (pts) with highrisk early breast cancer (BC) (2020) Schneeweiss A, Moebus V, Tesch H, Klare P, Denkert C, Kast K, Hanusch C, et al. Conference contribution Update Breast Cancer 2020 Part 1 – Early Breast Cancer: Consolidation of Knowledge About Known Therapies (2020) Schneeweiss A, Hartkopf AD, Mueller V, Woeckel A, Lux MP, Janni W, Ettl J, et al. Journal article, Review article Impact - Implementing Patients' Competence in Oral Breast Cancer Therapy - A Randomized, Controlled Study of Standardized Patient Coaching Versus Patient Management According to Local Practice for Patients with HR Positive HER2 Negative Metastatic Breast Cancer Treated with Abemaciclib (2020) Welslau M, Nabieva N, Decker T, Belleville E, Knapp O, Häberle L, Fasching P, Tesch H Conference contribution